ERIC L. MICHELSON, M.D.; WILLIAM H. FRISHMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Beta-adrenoceptor blockers are established drugs for the primary and adjunctive treatment of various cardiovascular disorders. These agents are useful in the management of patients with systemic hypertension, angina pectoris, hypertrophic cardiomyopathy, and a spectrum of cardiac dysrhythmias. Several beta-blockers have also shown "cardioprotective" effects in patients surviving a recent myocardial infarction, by reducing the incidence of death, sudden death, and reinfarction (1). Apparently, the major mechanism by which beta-blockers mediate their potent cardiovascular actions is via the competitive blockade of beta-1 adrenergic receptors that predominate in the heart. This hypothesis is not to discount the accumulating evidence of the additional
MICHELSON EL, FRISHMAN WH. Labetalol: An Alpha- and Beta-Adrenoceptor Blocking Drug. Ann Intern Med. 1983;99:553–555. doi: 10.7326/0003-4819-99-4-553
Download citation file:
Published: Ann Intern Med. 1983;99(4):553-555.
Cardiology, Coronary Risk Factors, HIV, Hypertension, Infectious Disease.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use